KR100691745B1 - 테크네튬-99m이 표지된 유기 게르마늄 화합물나노콜로이드, 이의 제조방법 및 용도 - Google Patents
테크네튬-99m이 표지된 유기 게르마늄 화합물나노콜로이드, 이의 제조방법 및 용도 Download PDFInfo
- Publication number
- KR100691745B1 KR100691745B1 KR1020060026508A KR20060026508A KR100691745B1 KR 100691745 B1 KR100691745 B1 KR 100691745B1 KR 1020060026508 A KR1020060026508 A KR 1020060026508A KR 20060026508 A KR20060026508 A KR 20060026508A KR 100691745 B1 KR100691745 B1 KR 100691745B1
- Authority
- KR
- South Korea
- Prior art keywords
- nanocolloid
- organic germanium
- technetium
- labeled
- germanium
- Prior art date
Links
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 title claims abstract description 33
- 229940056501 technetium 99m Drugs 0.000 title claims abstract description 32
- 229910052732 germanium Inorganic materials 0.000 title claims abstract description 21
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title description 3
- 150000002291 germanium compounds Chemical class 0.000 claims abstract description 36
- 210000000952 spleen Anatomy 0.000 claims abstract description 30
- 238000003384 imaging method Methods 0.000 claims abstract description 17
- 239000002872 contrast media Substances 0.000 claims abstract description 13
- 239000011734 sodium Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 12
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims abstract description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 9
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 9
- PKCYYRXPGMHIPO-UHFFFAOYSA-N 4-[[3-carboxypropyl(oxo)germyl]oxy-oxogermyl]butanoic acid Chemical compound OC(=O)CCC[Ge](=O)O[Ge](=O)CCCC(O)=O PKCYYRXPGMHIPO-UHFFFAOYSA-N 0.000 claims description 17
- 239000000084 colloidal system Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 229910052713 technetium Inorganic materials 0.000 claims description 4
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- VEYLRWJOBBCNNK-UHFFFAOYSA-J germanium(4+) 2-hydroxypropane-1,2,3-tricarboxylate 2-hydroxypropanoate Chemical class C(C(O)C)(=O)[O-].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Ge+4] VEYLRWJOBBCNNK-UHFFFAOYSA-J 0.000 claims 1
- 150000002894 organic compounds Chemical class 0.000 claims 1
- XEABSBMNTNXEJM-UHFFFAOYSA-N propagermanium Chemical compound OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O XEABSBMNTNXEJM-UHFFFAOYSA-N 0.000 claims 1
- 238000002372 labelling Methods 0.000 abstract description 18
- 229940121896 radiopharmaceutical Drugs 0.000 abstract description 15
- 239000012217 radiopharmaceutical Substances 0.000 abstract description 15
- 230000002799 radiopharmaceutical effect Effects 0.000 abstract description 15
- 229940039231 contrast media Drugs 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 8
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000009206 nuclear medicine Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- -1 technetium small molecule Chemical class 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940127043 diagnostic radiopharmaceutical Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- HVYWZJASVLEHGV-UHFFFAOYSA-N hydroxy(oxo)germane 2-hydroxypropane-1,2,3-tricarboxylic acid 2-hydroxypropanoic acid Chemical compound O[GeH]=O.CC(O)C(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O HVYWZJASVLEHGV-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- JEHASHUIFUSSAI-UHFFFAOYSA-N sulfanylidenetechnetium Chemical compound [Tc]=S JEHASHUIFUSSAI-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940127044 therapeutic radiopharmaceutical Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/30—Germanium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
크로마토그래피 시스템 | 99 mTc 화학종 | ||
지지체(support) | 용매 | 출발점(origin)에서의 검출양 | 용매선(solvent front)에서의 검출양 |
ITLC-SG ITLC-SG | MEK 생리식염수 | 99 mTc-Ge-132 100% 99 mTc-Ge-132 100% | 99 mTcO4 - 0% 99 mTcO4 0% |
시간(h) | 0.5 | 1 | 2 | 3 | 4 | 5 | 6 |
표지효율(%) | 100 | 100 | 100 | 100 | 100 | 100 | 99 |
Claims (9)
- 제1항에 있어서, 상기 화학식 1의 L로 표시되는 유기 게르마늄 화합물은 비 스-카복시에틸게르마늄 세스퀴옥사이드, 스피로게르마늄 및 유산-구연산-게르마늄산 염 중에서 선택되는 어느 하나인 것을 특징으로 하는 테크네튬-99m이 표지된 유기 게르마늄 화합물 나노콜로이드의 제조방법.
- 제1항에 있어서, 상기 단계 1의 유기 게르마늄 나노콜로이드 용액의 pH는 3.5 ~ 4.5의 범위 내인 것을 특징으로 하는 테크네튬-99m이 표지된 유기 게르마늄 나노콜로이드의 제조방법.
- 제1항에 있어서, 상기 단계 2의 용매는 산성 용매인 것을 특징으로 하는 테크네튬-99m이 표지된 유기 게르마늄 나노콜로이드의 제조방법.
- 제5항에 있어서, 상기 산성 용매는 염산, 질산 및 황산 중에서 선택되는 어느 하나인 것을 특징으로 하는 테크네튬-99m이 표지된 유기 게르마늄 나노콜로이드의 제조방법.
- 제1항의 화학식 1로 표시되는 테크네튬-99m이 표지된 유기 게르마늄 화합물 나노콜로이드를 포함하는 비장 영상화 조영제.
- 제8항에 있어서, 상기 테크네튬-99m이 표지된 유기 게르마늄 화합물 나노콜로이드는 제7항의 화학식 3으로 표시되는 99 mTc-비스-카복시에틸게르마늄 세스퀴옥사이드 나노콜로이드인 것을 특징으로 하는 비장 영상화 조영제.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060026508A KR100691745B1 (ko) | 2006-03-23 | 2006-03-23 | 테크네튬-99m이 표지된 유기 게르마늄 화합물나노콜로이드, 이의 제조방법 및 용도 |
US11/474,717 US7459141B2 (en) | 2006-03-23 | 2006-06-26 | Technetium-99m-labeled organic germanium nanocolloids, method of preparing the same and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060026508A KR100691745B1 (ko) | 2006-03-23 | 2006-03-23 | 테크네튬-99m이 표지된 유기 게르마늄 화합물나노콜로이드, 이의 제조방법 및 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100691745B1 true KR100691745B1 (ko) | 2007-03-12 |
Family
ID=38102852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060026508A KR100691745B1 (ko) | 2006-03-23 | 2006-03-23 | 테크네튬-99m이 표지된 유기 게르마늄 화합물나노콜로이드, 이의 제조방법 및 용도 |
Country Status (2)
Country | Link |
---|---|
US (1) | US7459141B2 (ko) |
KR (1) | KR100691745B1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101065865B1 (ko) | 2010-03-26 | 2011-09-20 | 전남대학교산학협력단 | 유기 게르마늄-티타노센 복합 화합물 및 이의 제조방법 |
KR101123855B1 (ko) | 2009-11-19 | 2012-03-16 | 전남대학교산학협력단 | 유기게르마늄이 함유된 복합재료 조성물 |
KR101221375B1 (ko) * | 2010-09-14 | 2013-01-11 | 전남대학교산학협력단 | 고휘도 청색 발광 나노콜로이드 및 이의 제조방법 |
KR101243609B1 (ko) | 2010-12-31 | 2013-03-14 | 전남대학교산학협력단 | 유기 게르마늄 나노구조체 및 이의 제조방법 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8668900B2 (en) | 2011-02-15 | 2014-03-11 | Kuwait University | Cancer-imaging agent and method of radioimaging using the same |
RU2543654C1 (ru) * | 2013-11-29 | 2015-03-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Национальный исследовательский Томский политехнический университет" | СПОСОБ ПОЛУЧЕНИЯ МЕЧЕННОГО ТЕХНЕЦИЕМ-99m НАНОКОЛЛОИДА |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050086065A (ko) * | 2004-02-24 | 2005-08-30 | 한국원자력연구소 | 테크네튬-안티모니 설파이드 나노콜로이드의 제조방법 |
-
2006
- 2006-03-23 KR KR1020060026508A patent/KR100691745B1/ko active IP Right Grant
- 2006-06-26 US US11/474,717 patent/US7459141B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050086065A (ko) * | 2004-02-24 | 2005-08-30 | 한국원자력연구소 | 테크네튬-안티모니 설파이드 나노콜로이드의 제조방법 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101123855B1 (ko) | 2009-11-19 | 2012-03-16 | 전남대학교산학협력단 | 유기게르마늄이 함유된 복합재료 조성물 |
KR101065865B1 (ko) | 2010-03-26 | 2011-09-20 | 전남대학교산학협력단 | 유기 게르마늄-티타노센 복합 화합물 및 이의 제조방법 |
KR101221375B1 (ko) * | 2010-09-14 | 2013-01-11 | 전남대학교산학협력단 | 고휘도 청색 발광 나노콜로이드 및 이의 제조방법 |
KR101243609B1 (ko) | 2010-12-31 | 2013-03-14 | 전남대학교산학협력단 | 유기 게르마늄 나노구조체 및 이의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
US20070224117A1 (en) | 2007-09-27 |
US7459141B2 (en) | 2008-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rösch et al. | The beginning and development of the theranostic approach in nuclear medicine, as exemplified by the radionuclide pair 86Y and 90Y | |
Haynes et al. | Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM | |
KR100650506B1 (ko) | 방사성 의약품용 레늄-트리카보닐 착물 및 그 전구체의제조방법 | |
KR100691745B1 (ko) | 테크네튬-99m이 표지된 유기 게르마늄 화합물나노콜로이드, 이의 제조방법 및 용도 | |
Reissig et al. | Recent insights in barium-131 as a diagnostic match for radium-223: Cyclotron production, separation, radiolabeling, and imaging | |
US20210379212A1 (en) | Stable, concentrated radionuclide complex solutions | |
JP7358451B2 (ja) | 安定な濃厚放射性核種錯体溶液 | |
Nishii et al. | Pharmacokinetics, metabolism, biodistribution, radiation dosimetry, and toxicology of 18 F-fluoroacetate (18 F-FACE) in non-human primates | |
US8937166B2 (en) | 68Ga generator | |
Vats et al. | Radiolabeling, stability studies, and pharmacokinetic evaluation of thulium-170-labeled acyclic and cyclic polyaminopolyphosphonic acids | |
McCarthy et al. | Nuclear medicine and positron emission tomography: an overview | |
US6503477B1 (en) | Radiopharmaceutical compositions | |
BAHRAMI et al. | Production, quality control and biological evaluation of 153Sm-EDTMP in wild-type rodents | |
Khalid et al. | Evaluation of carrier added and no carrier added 90 Y-EDTMP as bone seeking therapeutic radiopharmaceutical. | |
Karageorgou et al. | 99mTc-labeled iron oxide nanoparticles as dual-modality contrast agent: a preliminary study from synthesis to magnetic resonance and gamma-camera imaging in mice models | |
Wong et al. | Preparation and in vitro evaluation of neutron-activated, theranostic samarium-153-labeled microspheres for transarterial radioembolization of hepatocellular carcinoma and liver metastasis | |
Kaur et al. | Theranostics: New era in nuclear medicine and radiopharmaceuticals | |
Nassar et al. | Synthesis of a 188 Re–DTPMP complex using carrier-free 188 Re and study of its stability | |
Bouvry et al. | Labeling of hinokitiol with 90Y for potential radionuclide therapy of hepatocellular carcinoma | |
KR100724641B1 (ko) | 탄소나노튜브를 이용한 방사성 동위원소 표지화합물의제조방법 | |
KR100955665B1 (ko) | 테크네튬-99m 표지 산화철 나노입자의 제조방법 및 이를포함하는 암 질환의 진단용 영상화제 또는 치료제 | |
US20220080059A1 (en) | RADIOLABELING AND FORMULATION FOR SCALE UP OF 64Cu-DOTATATE | |
Happl et al. | Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103 | |
Talaat et al. | Preparation of 186Re-Cefixime as a potential diagnostic and therapeutic agent for bacterial infection | |
Chakraborty et al. | [sup. 177] Lu-EDTMP: a viable bone pain palliative in skeletal metastasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130111 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131227 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141230 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170111 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20171207 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190104 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 14 |